PillRx only · Patch, Extended Release · Transdermal
Clonidine
Clonidine
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$9.400
Latest avg · Jul 22, 2026
-6%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
46K
Rx · 2026 Q1
226K
Units dispensed
+23%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Dr.Reddy's laboratories Limited | unknown | 3 | SUPPLYING |
| Mayne Pharma Inc. | unknown | 0 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jun 9, 2022RECALLRecall (Class II): Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches (NDC 51862-455-01) per Carton (51862-455-04), Rx only, Manufa…
Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint. — Recalling firm: Mayne Pharma Inc — Nationwide in the US Market